← Alkermes plc (ALKS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alkermes plc (ALKS)
Pharmaceutical Preparations · market cap $7.1B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
20
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Alkermes plc (ALKS) is a fully-integrated biopharmaceutical company focused on psychiatric and neurological disorders, headquartered in Dublin with ~2,100 employees and a market cap of ~$8.66B. The company has marketed products (VIVITROL, and the LYBALVI franchise via ALKS 3831) alongside a broad pipeline, but carries net debt of ~$1.2B and a cash runway of only ~6.4 months, creating near-term financing pressure. The most important binary catalyst is an estimated September 2026 Phase 3 readout for ALKS 3831 (olanzapine/samidorphan) in schizophrenia, rated 9/10 impact, alongside multiple ALKS 2680 (narcolepsy) Phase 3 readouts in 2027.
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 2 · ALKS 2680imp 7/10
- 2027-05-15 (est.)Phase 3 · ALKS 2680 Dose 3imp 9/10
- 2027-06-15 (est.)Phase 3 · ALKS 2680 Dose 1imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VIVITROL® 380 mg | Phase 3 | Opiate Dependence |
| High Dose ALKS 5461 | Phase 3 | Major Depressive Disorder |
| ALKS 9072, Low Dose | Phase 3 | Schizophrenia |
| N1539 | Phase 2 | Hysterectomy |
| Paliperidone Palmitate | Phase 3 | Schizophrenia |
| ALKS 3831 | Phase 3 | Schizophrenia |
| ALK3831 | Phase 3 | Schizophrenia |
| OLZ/SAM | Phase 3 | Schizophrenia |
| VIVITROL 380 mg | Phase 3 | Alcohol Dependence |
| ALKS 37 | Phase 2 | Opioid-induced Constipation |
| ALKS 5461 | Phase 3 | Major Depressive Disorder |
| ALKS 9072 | Phase 3 | Schizophrenia |
| ALKS 2680 | Phase 2 | Narcolepsy Type 2 |
| NTX/BUP | Phase 3 | Opioid Use Disorder |
| Samidorphan (Low Dose) | Phase 2 | Schizophrenia |
| Motrin | Phase 2 | Dental Pain |
| ALKS 9072, Low | Phase 3 | Schizophrenia |
| TrIP-2D | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) |
| RDC-1036 (ALKS 37) | Phase 2 | Opioid-induced Constipation |
| RDC-0313 (ALKS 33) | Phase 2 | Binge Eating Disorder |
Price & technical context
3-month
-24.5%
6-month
+19.5%
12-month
+35.8%
52-wk range
$27.20–$55.22
vs 50-day MA
-11.3%
vs 200-day MA
+6.5%
Realized vol
39.9%
Max drawdown
-27.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALKS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.